

# Hai T Tran

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9127897/publications.pdf>

Version: 2024-02-01

36  
papers

3,397  
citations

331670

21  
h-index

361022

35  
g-index

36  
all docs

36  
docs citations

36  
times ranked

6249  
citing authors

#	ARTICLE	IF	CITATIONS
1	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. <i>Lung Cancer</i> , 2022, 164, 69-75.	2.0	2
2	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. <i>British Journal of Cancer</i> , 2022, 127, 569-576.	6.4	8
3	Pozotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. <i>Cancer Cell</i> , 2022, 40, 754-767.e6.	16.8	34
4	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 127-139.	1.1	48
5	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	30.7	357
6	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 601-609.	1.1	40
7	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2051-2064.	1.1	6
8	Plasma Based Protein Signatures Associated with Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3972.	3.7	2
9	Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. <i>JCO Precision Oncology</i> , 2021, 5, 1241-1249.	3.0	11
10	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	27.8	185
11	Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 349-357.	0.8	27
12	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	101
13	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020, 26, 5477-5486.	7.0	15
14	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
15	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. <i>Lung Cancer</i> , 2020, 146, 303-309.	2.0	2
16	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1449-1459.	1.1	109
17	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 423-436.	13.2	218
18	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 120, 340-345.	6.4	29

#	ARTICLE	IF	CITATIONS
19	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer. <i>JAMA Oncology</i> , 2019, 5, 67.	7.1	344
20	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2019, 20, 43-47.	2.6	45
21	COPD-Type lung inflammation promotes K-ras mutant lung cancer through epithelial HIF-1 $\alpha$ mediated tumor angiogenesis and proliferation. <i>Oncotarget</i> , 2018, 9, 32972-32983.	1.8	32
22	Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project. <i>Drugs in R and D</i> , 2017, 17, 211-218.	2.2	22
23	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with $\beta$ -blockers. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	96
24	Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 439-447.	2.0	20
25	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2016, 17, e5-e11.	2.6	39
26	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. <i>Clinical Cancer Research</i> , 2016, 22, 1940-1950.	7.0	15
27	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. <i>Clinical Cancer Research</i> , 2016, 22, 1103-1110.	7.0	326
28	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. <i>Cancer</i> , 2015, 121, 2968-2975.	4.1	22
29	Vandetanib and Indwelling Pleural Catheter for Non-small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion. <i>Clinical Lung Cancer</i> , 2014, 15, 379-386.	2.6	13
30	An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	7.0	848
31	Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 6067-6067.	1.6	2
32	A Practical Synthesis and X-ray Crystallographic Analysis of Dithymoquinone, a Photodimer of Thymoquinone. <i>Letters in Organic Chemistry</i> , 2012, 9, 762-766.	0.5	7
33	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. <i>Lancet Oncology</i> , The, 2012, 13, 827-837.	10.7	240
34	Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). <i>Investigational New Drugs</i> , 2011, 29, 499-505.	2.6	18
35	Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 308-314.	2.3	37
36	Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin. <i>Current Oncology Reports</i> , 2001, 3, 131-140.	4.0	44